heart iconheart icon
Share
Health & Wellness
Colleen A. Goggins on the Recent McNeil Consumer Healthcare Recall

Today Colleen Goggins, Worldwide Chairman, Consumer Group, Johnson & Johnson, is appearing before the U.S. House of Representatives Committee on Oversight and Government Reform to discuss the recent McNeil recall of certain infants’ and children’s products. Here are some excerpts from her testimony:

All of the Johnson & Johnson family of companies realize that we have a responsibility to provide consumers with the highest quality products possible, and we have worked hard to fulfill that responsibility for more than a century. We are proud that our products help millions of people around the world improve their health and well-being. Across our organization, we believe our first responsibility is to the doctors, nurses, and patients, to mothers and fathers, and all others who use our products and services. In this instance, we have not lived up to that responsibility, and the recall is therefore a disappointment to our Chairman Bill Weldon, to me personally, and to the thousands of employees in the Johnson & Johnson family of companies.

The quality and process issues that we found at McNeil, those which led to the recall and others, are unacceptable. On behalf of McNeil and Johnson & Johnson, I apologize to the mothers, fathers, and caregivers for the concern and inconvenience caused by the recall. Johnson & Johnson embraces the work of this Committee, and we hope that today’s hearing will be an important step in furthering public understanding of the recall.

Consistent with our goal of furthering public understanding, it is critical that the public understand that the recall was not undertaken on the basis of adverse medical events. Unfortunately, there has been some confusion in the media with respect to this recall. I would like to stress, therefore, four key points. First, as the FDA noted last month, the health risks to consumers from the recalled products were remote. Second, McNeil has no indication of a serious adverse medical event caused by any of the issues referenced in the recall announcement. Third, no raw materials that tested positive for objectionable bacteria were ever used in the manufacture of McNeil’s pediatric products. And finally, McNeil rejected the products that it found had excess active ingredient.

For further details, click here to read the full testimony.

Sign in to post a comment